Philips Q2 Net Income Slumps on One-Time Item; Margins and Cash Flow Show Gains

• Philips Q2 net income down 47% to €240M; adjusted EBITA up to €540M; free cash flow rebounds to €230M.

• Philips’ Q2 sales mixed: Personal Health +6%, margins shifted; Connected Care and Diagnosis sales down, margins improved; mature markets flat, growth regions +2%.

• Philips posts €86M charges; hikes full-year margin guidance to 11.3%-11.8%, maintains sales growth outlook, expects €0.2-0.4B free cash flow.

Royal Philips announced a 47% drop in net income for the second quarter, with earnings falling to €240 million from €452 million in the same period last year. This decline primarily stems from the absence of a €538 million one-off insurance gain recorded in the prior year linked to the Philips Respironics recall. Operating income also fell markedly to €400 million from €816 million.

Despite the drop in net income, adjusted EBITA rose to €540 million from €495 million, while the adjusted EBITA margin improved to 12.4% from 11.1%. Group sales decreased 3% to €4.34 billion but were up 1% on a comparable basis. Free cash flow rebounded to €230 million, recovering from a negative €64 million, and operating cash flow climbed to €387 million from €89 million.

Philips' segment results were varied in the quarter. Personal Health sales increased 6% on a comparable basis to €862 million, up from €834 million, but its adjusted EBITA margin declined to 15.2% from 16.9% due to higher advertising and promotional costs. Connected Care posted lower sales at €1.27 billion compared with €1.33 billion previously, though its margin improved to 10.4% from 8.8%. Diagnosis & Treatment sales fell to €2.08 billion from €2.17 billion, but margin expanded to 13.5% from 12.2%.

On a geographical level, mature markets saw flat comparable sales while growth regions advanced 2%, despite weaker performance in China. North America and Western Europe recorded no growth on a comparable basis, with total sales slipping 4% and 1%, respectively.

Philips incurred €86 million in charges during the quarter, including €46 million related to restructuring and acquisition expenses, €34 million in field action costs, €21 million linked to a consent decree, and a €23 million gain from a contract settlement. The Dutch firm reaffirmed its full-year comparable sales growth guidance of 1% to 3%, while upgrading its adjusted EBITA margin forecast to a range of 11.3% to 11.8%, up from 10.8% to 11.3%.

This revision factors in a decreased estimated tariff impact of €150 million to €200 million, compared to a prior estimate of €250 million to €300 million. Free cash flow is now expected between €0.2 billion and €0.4 billion for the full year. The company’s outlook excludes potential effects from ongoing regulatory and legal matters concerning Philips Respironics, including a U.S. Department of Justice probe. Additionally, Philips paid a €0.85 dividend per share for 2024 in the second quarter, with 41.4% distributed in cash and the remainder as shares.